Literature DB >> 16365611

Therapeutic goal attainment in patients with hypertension and dyslipidemia.

Michael L Johnson1, Kenneth Pietz, David S Battleman, Rebecca J Beyth.   

Abstract

BACKGROUND: Recent guidelines emphasize the need to assess and treat overall risk for cardiovascular disease through the concomitant management of multiple risk factors. We sought to ascertain treatment patterns and attainment of therapeutic goals in patients with isolated and concomitant hypertension and dyslipidemia, both with and without diabetes mellitus (DM) and symptomatic cardiovascular disease.
METHODS: Inception cohorts of more than 41,000 newly diagnosed hypertension and dyslipidemia patients from 6 medical centers of the south-central Veterans Affairs health care system were evaluated. Treatment patterns and goal attainment for low-density lipoprotein cholesterol (LDL-C; Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults guidelines: <160, <130, or <or=100 mg/dL depending on risk factors) and blood pressure (BP; Joint National Committee 6: <140/90 or <130/85 mm Hg depending on risk factors) were measured at 1 year. Separate analyses were conducted in patients with and without DM and symptomatic cardiovascular disease.
RESULTS: Treatment rates in patients with and without DM and symptomatic disease ranged from 46.6% to 71.3% in patients with hypertension only, from 31.5% to 64.1% in patients with dyslipidemia only, and from 64.3% to 91.3% in patients with both conditions. Among asymptomatic patients, 40.6% of nondiabetics and 20.6% of patients with DM with isolated hypertension reached BP targets. Attainment of LDL-C goals was slightly higher and reached 52.8% among patients with DM with concomitant hypertension. Among symptomatic patients, attainment of all goals was <40% for all groups. The proportion of asymptomatic patients with concomitant disease reaching goal for both BP and LDL-C was 24.4% among nondiabetics and 15.4% among patients with DM; these proportions decreased to 13.6% and 13.4% respectively, among patients with symptomatic cardiovascular disease.
CONCLUSIONS: The majority of patients were receiving pharmacological treatment of hypertension and dyslipidemia, yet attainment of therapeutic goals was generally <50%. Further work is needed to determine factors related to improvement in management and outcomes of patients with multiple cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365611     DOI: 10.1097/01.mlr.0000188982.25397.37

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  19 in total

Review 1.  Expanding the definition of hypertension to incorporate global cardiovascular risk.

Authors:  Nitin Khosla; Henry R Black
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

2.  Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

Authors:  Thomas M MacDonald; Steven V Morant
Journal:  Br J Clin Pharmacol       Date:  2008-02-14       Impact factor: 4.335

3.  Quality of cardiovascular care in an internal medicine resident clinic.

Authors:  Eileen Masterson; Priyanka Patel; Yen-Hong Kuo; Charles K Francis
Journal:  J Grad Med Educ       Date:  2010-09

4.  Telemedicine cardiovascular risk reduction in veterans.

Authors:  S Dee Melnyk; Leah L Zullig; Felicia McCant; Susanne Danus; Eugene Oddone; Lori Bastian; Maren Olsen; Karen M Stechuchak; David Edelman; Susan Rakley; Miriam Morey; Hayden B Bosworth
Journal:  Am Heart J       Date:  2013-02-28       Impact factor: 4.749

5.  Health beliefs and desire to improve cholesterol levels among patients with hyperlipidemia.

Authors:  Leah L Zullig; Linda L Sanders; Steven Thomas; Jamie N Brown; Susanne Danus; Felicia McCant; Hayden B Bosworth
Journal:  Patient Educ Couns       Date:  2015-11-27

6.  The effect of a hypertension self-management intervention on diabetes and cholesterol control.

Authors:  Benjamin J Powers; Maren K Olsen; Eugene Z Oddone; Hayden B Bosworth
Journal:  Am J Med       Date:  2009-07       Impact factor: 4.965

Review 7.  Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2010       Impact factor: 9.546

8.  Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.

Authors:  Joel M Neutel; Michael Eaddy; Orsolya E Lunacsek; Craig Roberts; Linda Chen; Allison J Kean; James H Jackson
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738

9.  Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

Authors:  Richard H Chapman; Elise M Pelletier; Paula J Smith; Craig S Roberts
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

10.  A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.

Authors:  Woohyeun Kim; Kiyuk Chang; Eun Joo Cho; Jeong-Cheon Ahn; Cheol Woong Yu; Kyoung-Im Cho; Yong-Jin Kim; Duk-Hyun Kang; Seok-Yeon Kim; Sang-Hak Lee; Ung Kim; Shin-Jae Kim; Young Keun Ahn; Chang Hoon Lee; Jin Ho Shin; Mikyung Kim; Chang Gyu Park
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.